The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies | Zendy

Richard Copin | Zendy; Alina Baum | Zendy; Elzbieta Wloga | Zendy; Kristen E. Pascal | Zendy; Stephanie Giordano | Zendy; Benjamin O. Fulton | Zendy; Anbo Zhou | Zendy; Nicole Negron | Zendy; Kathryn Lanza | Zendy; Newton Chan | Zendy; Angel Coppola | Zendy; Joyce Chiu | Zendy; Min Ni | Zendy; Yi Wei | Zendy; Gurinder S. Atwal | Zendy; Annabel Romero Hernandez | Zendy; Kei Saotome | Zendy; Yi Zhou | Zendy; Matthew C. Franklin | Zendy; Andrea T. Hooper | Zendy; Shane McCarthy | Zendy; Sara Hamon | Zendy; Jennifer D. Hamilton | Zendy; Hilary Staples | Zendy; Kendra J. Alfson | Zendy; Ricardo Carrion | Zendy; Shazia Ali | Zendy; Thomas Norton | Zendy; Selin Somersan-Karakaya | Zendy; Sumathi Sivapalasingam | Zendy; Gary Herman | Zendy; David M. Weinreich | Zendy; Leah Lipsich | Zendy; Neil Stahl | Zendy; Andrew Murphy | Zendy; George D. Yancopoulos | Zendy; Christos A. Kyratsous | Zendy

Open Access

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies

Author(s) -

Richard Copin,

Alina Baum,

Elzbieta Wloga,

Kristen E. Pascal,

Stephanie Giordano,

Benjamin O. Fulton,

Anbo Zhou,

Nicole Negron,

Kathryn Lanza,

Newton Chan,

Angel Coppola,

Joyce Chiu,

Min Ni,

Yi Wei,

Gurinder S. Atwal,

Annabel Romero Hernandez,

Kei Saotome,

Yi Zhou,

Matthew C. Franklin,

Andrea T. Hooper,

Shane McCarthy,

Sara Hamon,

Jennifer D. Hamilton,

Hilary Staples,

Kendra J. Alfson,

Ricardo Carrion,

Shazia Ali,

Thomas Norton,

Selin Somersan-Karakaya,

Sumathi Sivapalasingam,

Gary Herman,

David M. Weinreich,

Leah Lipsich,

Neil Stahl,

Andrew Murphy,

George D. Yancopoulos,

Christos A. Kyratsous

Publication year - 2021

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2021.06.002

Subject(s) - biology , monoclonal antibody , virology , antibody , virus , pandemic , population , covid-19 , hamster , monoclonal , immunology , microbiology and biotechnology , infectious disease (medical specialty) , disease , medicine , demography , pathology , sociology

Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the combination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2 variants of concern/interest and also protects against emergence of new variants and their potential seeding into the population in a clinical setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research